Efficacy and Safety of [¹⁷⁷Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review.

ABSTRACT:

Background

We have performed a systematic review to evaluate the efficacy and safety of [¹⁷⁷Lu]Lu-DOTA-TATE, a radioligand therapy, in advanced somatostatin receptor-positive pheochromocytoma/paraganglioma (PPGL), thymic neuroendocrine tumor (NET), bronchial NET, unknown primary NET, or medullary thyroid carcinoma (MTC).

Methods

Studies identified in PubMed from inception to 13 May 2021 must have assessed [¹⁷⁷Lu]Lu-DOTA-TATE as a single agent and reported outcome data for the specific NET types of interest.

Results

Two independent reviewers performed the screening and data extraction, resulting in 16 publications: PPGL (n = 7), bronchial NETs (n = 6; one also included NETs of unknown origin), and MTC (n = 3). Overall, [¹

SUBMITTER: Hertelendi M 

PROVIDER: S-EPMC10135775 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature